Cover Image

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2- breast cancer treated with CDK4/6 inhibitors and endocrine therapy

Background: Advanced breast cancer (ABC) is characterized by multidimensional clinical complexity that is usually not considered in randomized clinical trials. In the present real-life study, we investigated the link between clinical complexity and quality of life of patients with HR+/HER2- ABC trea...

Full description

Saved in:

Bibliographic Details
Main Authors:	Barbara Tagliaferri (Author), Ludovica Mollica (Author), Raffella Palumbo (Author), Claudia Leli (Author), Alberto Malovini (Author), Matteo Terzaghi (Author), Erica Quaquarini (Author), Cristina Teragni (Author), Stefano Maccarone (Author), Andrea Premoli (Author), Federico Sottotetti (Author)
Format:	Book
Published:	BioExcel Publishing Ltd, 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2- metastatic breast cancer: a prospective, monocentric study
by: Raffaella Palumbo, et al.
Published: (2024)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
by: Federico Sottotetti, et al.
Published: (2022)

Palbociclib in metastatic breast cancer: current evidence and real-life data
by: Francesco Serra, et al.
Published: (2019)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
by: Corona SP, et al.
Published: (2018)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
by: Palumbo R, et al.
Published: (2015)

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
by: Lu-Qi Cao, et al.
Published: (2024)

Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis
by: Ludovica Mollica, et al.
Published: (2021)

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
by: Dongqing Pu, et al.
Published: (2024)

Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis
by: Zhihao Zhang, et al.
Published: (2024)

Clinical Outcome of Combinations of Endocrine Therapy with Targeted Therapy in Women with HR +/ HER2 - Postmenopausal Advanced Breast Cancer: A Systematic Review and Meta-analysis
by: Anahita Shirvani, et al.
Published: (2024)

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors
by: Mariane Teodoro Fernandes, et al.
Published: (2018)

Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node-Positive HR+, HER2− Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta-Analysis
by: Mahtab Vasigh, et al.
Published: (2024)

Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution
by: Maria Inês Teodoro, et al.
Published: (2024)

Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer
by: Edoardo Mortato, et al.
Published: (2024)

Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review
by: Federica Martorana, et al.
Published: (2024)

HR+/HER2- de novo metastatic breast cancer: a true peculiar entity?
by: Rosalba Torrisi, et al.
Published: (2023)

Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis
by: Xin Guan, et al.
Published: (2024)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018)

Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings
by: Nina Galipeau, et al.
Published: (2019)

Jewel: A Chapter in Her Life
by: Burnham, Clara Louise, 1854-1927

Woman Her Sex and Love Life
by: Robinson, William J. (William Josephus), 1867-1936

Life of Her Majesty Queen Victoria
by: Fawcett, Millicent Garrett, Dame, 1847-1929

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
by: Duan F, et al.
Published: (2021)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain
by: Galve-Calvo E, et al.
Published: (2018)

Jeanne D'Arc: Her Life And Death
by: Oliphant, Mrs. (Margaret), 1828-1897

Jessica Trent: Her Life on a Ranch
by: Raymond, Evelyn, 1843-1910

Her Benny: A Story of Street Life
by: Hocking, Silas K. (Silas Kitto), 1850-1935; Tuck, Harry [Illustrator]

Life of Octavia Hill as Told in Her Letters
by: Hill, Octavia, 1838-1912; Maurice, C. Edmund (Charles Edmund), 1843-1927 [Editor]

The Portrait of Qiong Yao's Life in Her Novels
by: Cendrawaty Cendrawaty, et al.
Published: (2009)

Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
by: I. V. Kolyadina
Published: (2021)

Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions
by: Elena Peruzzi, et al.
Published: (2024)

Early-life exposure to endocrine disrupting chemicals associates with childhood obesity
by: Chunxue Yang, et al.
Published: (2018)

George Sand: Some Aspects of Her Life and Writings
by: Doumic, René, 1860-1937; Hallard, Alys [Translator]

Louisa May Alcott : Her Life, Letters, and Journals
by: Alcott, Louisa May, 1832-1888; Cheney, Ednah Dow, 1824-1904 [Editor]

Tried for Her Life A Sequel to "Cruel As the Grave"
by: Southworth, Emma Dorothy Eliza Nevitte, 1819-1899

The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer
by: Mirosława Püsküllüoğlu, et al.
Published: (2024)

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
by: Ratnakar Reddy Kuchukulla, et al.
Published: (2022)

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database
by: Rachel Prevost, et al.
Published: (2023)

Current evidence for the roles of early-life endocrine disruptors on pubertal timing in girls
by: Jeong Eun Lee, et al.
Published: (2019)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020)